Jean-Jacques Kiladjian: Interferon-Alpha in Polycythemia Vera Balancing Efficacy and Autoimmune Risk
Jean-Jacques Kiladjian, Head of Clinical Research Department of Inserm, Professor of Medicine at the University of Paris Cité, President of the FIM, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in HemaSphere, adding:
“Interferon-alpha is a major treatment for Polycythemia Vera, but its use requires some precautions, particularly due to its immunomodulatory properties. In this article, we review the immune-related complications associated with interferon-alpha therapy and discuss strategies for their prevention and management.
A pre-treatment evaluation is necessary, and discussion with a specialist is often helpful to determine whether interferon can be safely used and how patients should be monitored in the presence of pre-existing autoimmune disease or signs of autoimmunity.”
Title: Autoimmunity and peginterferon therapy for polycythemia vera
Authors: Etienne Rivière, Alexandre Guy, Olivier Mansier, Clémence Mediavilla, Jean-Jacques Kiladjian, Chloé James, Patrick Blanco, Estibaliz Lazaro, Jean-François Viallard

More posts featuring Jean Jacques Kiladjian on Hemostasis Today.
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C